| Document |
Document Title |
|
WO/2024/064763A2 |
Variants of coagulation factor VIII (FVIII) and expression cassettes encoding the FVIII variants thereof are described. A variant FVIII includes a glycoepitope of the FVIII protein including an N2118Q mutation. The N2118Q mutation can be...
|
|
WO/2024/064931A1 |
The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivery of Plasmodium protein antigens and related technologies (e.g., components thereof and/or methods relating thereto). Among other things, the pre...
|
|
WO/2024/064913A1 |
The present disclosure provides gene therapy vectors, such as recombinant adeno-associated virus (rAAV) for expressing a human micro-dystrophin gene. The present disclosure also provides compositions and methods of using these rAAV to tr...
|
|
WO/2024/064756A1 |
Disclosed are bispecific modulators. Bispecific modulators can bind to a protein of interest and to an internalizing receptor on a cell surface. Once bound, the protein of interest can be internalized and/or degraded inside a cell.
|
|
WO/2024/064200A2 |
The present disclosure provides compositions comprising a designed ankyrin repeat protein (DARPin) for use in treating Shiga toxin (Stx)-producing Escherichia coli (STEC) and related diseases, including hemolytic uremic syndrome (HUS). T...
|
|
WO/2024/064922A2 |
Compositions and methods for treating insulin resistance, reducing blood glucose level, increasing insulin tolerance, and treating diabetes. The methods include administering the composition to a subject. The subject may express insulin ...
|
|
WO/2024/064838A1 |
Provided herein are lipid particles, including viral-based particles, comprising Paramyxovirus glycoproteins having reduced glycosylation, and in some aspects, comprise variant G/H proteins. Also provided are methods for producing and mo...
|
|
WO/2024/061930A1 |
The present invention relates to treatment and diagnostic of peripheral t-cell lymphoma (PTCL). In this study, the inventors showed that cutaneous T-cell lymphoma (CTCL) lines and KIR3DL2+ SC are ICOS+ and ICOSL+. Normal T lymphocytes ar...
|
|
WO/2024/062259A1 |
The present invention relates to retroviral vectors modified to improve transgene expression. In particular, the invention relates to retroviral vectors lacking an endogenous Rev response element (RRE) and comprising an intron, particula...
|
|
WO/2024/064716A2 |
Isolated T cell receptors (TCRs) that specifically recognize a peptide derived from an HPV E6 or E7 protein are described. The TCRs include an alpha chain variable region and a beta chain variable region having the complementarity determ...
|
|
WO/2024/060948A1 |
The present invention relates to a T cell receptor (TCR) specifically binding to a human papillomavirus E7, a nucleic acid encoding the TCR, an engineered cell comprising same, and a method for preparing the engineered cell. The present ...
|
|
WO/2024/063538A1 |
The present invention relates to a composition for base editing of plant cell organelle DNA and, in particular, to a composition and method for editing adenine to guanine and cytosine to thymine in plant cell organelle DNA.
|
|
WO/2024/064855A2 |
The present application relates to chimeric antigen receptors (CARs), engineered immune cells (e.g., NK cells, NKT cells, and T cells), and methods of use thereof. The CARs provided herein can enhance the killing activities of the engine...
|
|
WO/2024/061310A1 |
The present invention provides a dual GLP-1 and GIP receptor agonist pharmaceutical composition, comprising a dual GLP-1 and GIP receptor agonist, a stabilizer, and a buffer salt. The present invention also provides a use of the pharmace...
|
|
WO/2024/064713A1 |
The disclosure provides antibodies or antigen-binding domains thereof specific for CD228 and fusion proteins specific for both CD137 and CD228, which fusion proteins can be used to co-stimulate lymphocyte activation in a CD228-target-dep...
|
|
WO/2024/064733A2 |
Genetically engineered immune cells (e.g., T cells or NK cells) expressing anti-BCMA, anti-TACI, or anti-BCMA/anti-TACI chimeric antigen receptors and uses thereof in cancer therapy. In some embodiments, the genetically engineered immune...
|
|
WO/2024/064752A2 |
Bio-adhesive derived from Vibrio cholerae (Vc) are provided. In some forms, the bio-adhesive includes a sequence of 57 amino acids within a major biofilm adhesin Bap1, and sequence variations thereof, that can be used as bioactive glue t...
|
|
WO/2024/063404A1 |
The present invention relates to a method for cultivating a botulinum toxin-producing strain to increase botulinum toxin productivity and to a method for effectively producing botulinum toxin by culturing a strain using the method. Throu...
|
|
WO/2024/061188A1 |
The present invention provides a coronavirus multivalent vaccine and use thereof. The coronavirus multivalent vaccine comprises a coronavirus Spike protein extracellular domain containing a mutation, a truncated fragment thereof, or a fu...
|
|
WO/2024/064839A2 |
Some aspects of the present disclosure are directed towards the concentration or reduction of a solution, formulation, mixture, or compound comprising a protein conjugated to a polymer. In some embodiments, the method can involve applyin...
|
|
WO/2024/060167A1 |
The present invention provides a fusion protein, which comprises: a tissue plasminogen activator or a variant thereof; a disintegrin or a variant thereof; and a connector. The connector connects the tissue plasminogen activator or the va...
|
|
WO/2024/064753A1 |
Disclosed are receptor traps that regulate immune cells. The receptor traps can have an ectodomain from a tumor cell that can bind to a chimeric antigen receptor (CAR) on a CAR-T cell that reversibly inhibits activation of the CAR-T cell.
|
|
WO/2024/062101A1 |
The invention relates to a bi-specific agent, comprising an anchor region capable of binding a plasma cell, and a binding region associated with the anchor region, wherein the binding region comprises an epitope of an interferon, an inte...
|
|
WO/2024/061757A1 |
The present invention relates to stabilized human parainfluenza virus 1 (HPIV1) F protein, and to nucleic acid sequences encoding such proteins, as well as to uses of said proteins and nucleic acid sequences.
|
|
WO/2024/060538A1 |
Provided are use of Flotillin1 gene and Importinα4 gene, and use of a molecule for inhibiting the transcription or translation of Flotillin1 gene and Importinα4 gene in preparing a kit. The present invention also relates to a method fo...
|
|
WO/2024/060118A1 |
The present disclosure provides a method for preventing, ameliorating, and/or treating a sleeping disorder in a subject in need of such prevention, amelioration, and/or treatment, comprising administering to a subject an effective amount...
|
|
WO/2024/061759A1 |
The present invention relates to stabilized HCoV-NL63 S proteins, or fragments thereof, nucleic acid sequences encoding such proteins, as well as to uses thereof.
|
|
WO/2024/056738A1 |
The present invention relates to an allogeneic myeloid cell, such as a macrophage, for use in therapy, such as the treatment of cancer in a human patient, wherein the allogeneic myeloid cell, such as the allogeneic macrophage, comprises ...
|
|
WO/2024/059227A2 |
|
|
WO/2024/055429A1 |
Disclosed in the present invention are an SARS-COV-2 antigen polypeptide, a recombinant adeno-associated virus and the use thereof. The present invention uses an S protein or RBD of the SARS-COV-2 antigen polypeptide as an antigen. A tru...
|
|
WO/2024/058178A1 |
The present invention provides a reagent that is for measuring an epidermal growth factor receptor tyrosine kinase activity and that contains: a modified polypeptide to which an acceptor and a donor inducing Förster resonance energy tra...
|
|
WO/2024/059686A2 |
Disclosed herein are DARPin backbones that form multimer and self-assembling protein cages that comprise proteins, which comprise DARPin backbones, fused to subunit proteins of the self-assembling protein cages and methods of making and ...
|
|
WO/2024/055075A1 |
The present invention relates to radiolabelled molecules, and related precursor molecules, for use in detecting immune cells expressing a receptor comprising an antigen binding site for binding to dysfunctional P2X7 receptor and a signal...
|
|
WO/2024/059507A1 |
The disclosure provides a complex comprising (a) a first monomer comprising an Fc domain fused to two FGF21 domains comprising the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4, which may be the same or different, and (b) a second ...
|
|
WO/2024/058589A1 |
The present invention relates to a chimeric antigen receptor (CAR) cell prepared using genetic scissor knock-in, and a use thereof, and more specifically to a method for preparing a single guide RNA (sgRNA) for TGF beta receptor 2 (TGFBR...
|
|
WO/2024/059787A1 |
The application relates to modified immune effector cells with enhanced immune cell function, as well as related pharmaceutical compositions. The application further relates to methods for generating the modified immune effector cell and...
|
|
WO/2024/055108A1 |
Compounds, compositions, uses, and methods for reducing cell viability of a cancer cell, or for preventing or treating cancer, are provided herein. In certain examples, methods for reducing cell viability of a cancer cell and/or for prev...
|
|
WO/2024/059733A2 |
Chimeric antigen receptors (CAR) with a binding domain that binds Nectin-4 are disclosed. The Nectin-4 binding domain can be derived from the murine antibody M22-321b41.1. The CAR disclosed herein can be expressed by an immune cell to be...
|
|
WO/2024/059674A1 |
The present invention relates to a pharmaceutical composition comprising a dual incretin peptide that agonizes receptors for both human glucose dependent insulinotropic polypeptide (GIP) and glucagon like peptide 1 (GLP-1).
|
|
WO/2024/059634A2 |
The present application provides for polypeptides comprising an IL-21 polypeptide, IL-12 polypeptide, and/or a IL-15 polypeptide, and/or a IL-15 receptor polypeptide; immune checkpoint polypeptides; compositions comprising the same; and ...
|
|
WO/2024/056874A1 |
The present invention relates to polypeptides comprising a first amino acid sequence comprising one or more GG repeat sequences and a peptide or polypeptide of interest in form of a fusion protein that exhibits increased renaturation eff...
|
|
WO/2024/055077A1 |
The invention relates to fusion proteins and uses thereof for obtaining and isolating enriched populations of immune cells. Exemplified fusion proteins include those comprising a dysfunctional purinergic P2X7 receptor (P2X7R) epitope moi...
|
|
WO/2024/059517A1 |
Described herein are CB5 polypeptides for the biosynthesis of oxygenated hydrocarbons in modified host cells.
|
|
WO/2024/056979A1 |
The invention relates to a hybrid molecule comprising at least one antibody Fc portion covalently bound to at least one peptide binding to a self-reactive lymphocyte involved in autoimmune vasculitis, to the uses of such a hybrid molecul...
|
|
WO/2024/059486A1 |
A method of delivering fish DNA vaccines is provided, wherein the vaccines are delivered intramuscularly in a plurality of injections.
|
|
WO/2024/059149A2 |
Provided are fusion proteins including an amino acid sequence of an ectodomain of Spike protein of a coronavirus, such as SARS-CoV-2, joined to an amino acid sequence of a ferritin subunit polypeptide. Nanoparticles including such fusion...
|
|
WO/2024/059286A1 |
Disclosed in certain embodiments herein is a formulation including a plant-based growth factor and at least one of a peptide, an antioxidant and a botanical agent. The formulation has been found to improve the properties of the skin on t...
|
|
WO/2024/059621A2 |
The present invention provides compositions and methods of treating cancer associated with mutant RAS. In certain aspects, the present invention provides T-cell receptors that bind to specific mutant RAS peptide fragments in the context ...
|
|
WO/2024/055179A1 |
Provided are a target GPNMB for resistance against PD-1 antibody therapies and use of the target in reversing secondary resistance against PD-1 antibody therapies.
|
|
WO/2024/059161A1 |
The present disclosure provides novel methods for serotype-specific analysis of compositions comprising one or more polysaccharides. The polysaccharide content can exist as free polysaccharides, or polysaccharide in other forms, such as ...
|
